Evidence map›Paper›PMID 34524695›Full record

ArticleJournal of medical virology2022

Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.

Yutaro Kitagawa, Kazuo Imai, Masaru Matsuoka, Ai Fukada, Katsumi Kubota, Momoko Sato, Tomohito Takada, Sakiko Noguchi, Norihito Tarumoto, Shigefumi Maesaki and 2 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yutaro KitagawaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Kazuo ImaiDepartment of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.ORCID 0000-0002-8416-7371
Masaru MatsuokaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Ai FukadaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Katsumi KubotaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Momoko SatoDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Tomohito TakadaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Sakiko NoguchiDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Norihito TarumotoDepartment of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
Shigefumi MaesakiDepartment of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan.
Shinichi TakeuchiDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Takuya MaedaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.ORCID 0000-0003-0912-4643
Saitama Medical University Hospital · JPSaitama Medical University · JPSelf-Defense Forces Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fully automated immunoassays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies that are strongly correlated with neutralization antibodies (nAbs) are clinically important because they enable the assessment of humoral immunity after infection and vaccination. Access SARS-CoV-2 immunoglobulin M (IgM) and immunoglobulin G (IgG) II antibody tests are semi-quantitative, fully automated immunoassays that detect anti-receptor-binding domain (RBD) antibodies and might reflect nAb levels in coronavirus disease 2019 (COVID-19). However, no studies have investigated the clinical utility of these tests in association with nAbs to date. To evaluate the clinical utility of Access SARS-CoV-2 IgM and IgG II antibody tests and their correlation with the SARS-CoV-2 surrogate virus neutralization test (sVNT) that measures nAbs in patients with COVID-19, we analyzed 54 convalescent serum samples from COVID-19 patients and 89 serum samples from non-COVID-19 patients. The presence of anti-RBD antibodies was detected using Access SARS-CoV-2 IgM and IgG II antibody tests, while nAbs were measured by sVNT. The sensitivity and specificity of sVNT were 94.4% and 98.9%, respectively. There were strong positive correlations between the inhibition values of sVNT and the results of the Access SARS-CoV-2 IgM (R = 0.95, R

Indexed as

AdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralCOVID-19FemaleHumansImmunoassayImmunoglobulin GImmunoglobulin MMaleMiddle AgedNeutralization TestsSARS-CoV-2Sensitivity and SpecificityAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19IgGIgMneutralization antibodySARS-CoV-2

Identifiers

PMID34524695
PMCPMC8661952
OpenAlexW3199823777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.